Trial intelligence / Profile preview

SYMBIOTIC-GI-16: PF-08634404 plus chemotherapy in first-line advanced gastroesophageal adenocarcinoma

2025-524717-86-00Phase 3Authorised

Sponsor: Pfizer
Start: Sep 2026
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Countries: 9

Overview

Phase 3, randomised trial of PF-08634404 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Pfizer. Primary endpoints: Confirmed objective response rate, Adverse events and 2 more. Planned start Sep 2026; status: authorised.

Drugs

PF-08634404

Conditions

gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)

Beyond the preview

Go deeper on 2025-524717-86-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-524717-86-00.